Glioblastoma Market by Product, End-User, Future Insights, Competitive Landscape and Forecast to 2025
Market Highlights:
The global Glioblastoma Market is expected to register
a CAGR of 7.40% during the forecast period with a market value
of USD 1,643.4 million till 2025. Glioblastoma is a malignant grade IV tumor.
The increasing incidence rates, the rise in product approvals, and growing
research in the field are projected to drive the growth of the global
glioblastoma market. On the other hand, the termination of many clinical trial
drug candidates is anticipated to hamper the growth of the market.
Get Full Report Details and TOC Exclusively @ https://www.marketresearchfuture.com/reports/glioblastoma-market-8307
Key Players:
·
F. Hoffmann-La Roche Ltd
·
Amgen Inc
·
Arbor Pharmaceuticals
·
Sun Pharmaceutical
Industries Ltd
·
Merck & Co
·
Teva Pharmaceutical
Industries Ltd
Regional Analysis:
The
global glioblastoma market, based on region, has been divided into the
Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The
Americas is likely to hold the largest share of the global glioblastoma market
during the assessment period. The increasing
incidence rate of glioblastoma and high funding for research & development
projects in the US and Canada are likely to support the dominance of the
Americas during the forecast period. The approval of drugs in these
countries help in maximizing the growth of the market in this region as well.
The Europe
market established substantial growth in
the market due to the increasing number
of clinical trials in this region.
Asia-Pacific
is estimated to be the fastest-growing region in the global market due to the huge patient population, improving healthcare
infrastructure, and growing per capita disposable incomes.
The glioblastoma
market in the Middle East & Africa is expected to witness gradual growth due to the increasing availability of
new treatment methods.
Related
Reports
Comments
Post a Comment